Patrick LOVE Evonne

# Patrick Yihong Wu

College of Medicine, National Taiwan University

# Evonne Hsiaoyun Hung

College of Dentistry, National Taiwan University

Introduction to CKD and Frailty

Chronic kidney disease is also called chronic kidney fail- ure, including symptoms such as gradual loss of kidney func- tion, and advanced stage of CKD indicates a dangerous level of fluid, electrolytes and wastes accumulate in body. How- ever,d the early stage of the disease doesn’t usually manifest signs.

Treatment often focuses on halting the process of fail- ure by treating the underlying cause. Without good control, CKD progresses to end-stage kidney failure (ESKD), and if no transplant or artificial dialysis often leads to death.

Symptoms and signs of CKD involve nausea, vomit- ing, loss of appetite, fatigue and weakness, sleep problems, changes in how much you urinate, decreased mental sharp- ness, muscle twitches and cramps, swelling of feet and an- kles, persistent itching, chest pain if fluid builds up around the lining of the heart, shortness of breath if fluid builds up in the lungs, high blood pressure (hypertension) that’s diffi- cult to control. But because kidney is exceedingly malleable, signs may not develop until irrevocable damage has been made. Sometimes even failures have developed, amount of urine stay normal, however, wastes are not sufficiently ex- creted.

Causes related to CKD are Type I or II diabetes, high B.P., glomerulonephritis, interstitial nephritis, polycystic kidney disease, prolonged obstruction of the urinary tract (usually caused by enlarged prostate, kidney stones and some can- cers), vesicoureteral reflux (a disorder that makes urine back up into kidneys), recurrent kidney infection which is also called pyelonephritis. Risk factors that may increase the risk of CKD are diabetes, high B.P.., cardiovascular disease, smoking, obesity, being African-American, Native American or Asian-American, family history of KD, abnormal kidney structure, older age [a1]. Frailty is a geriatric condition in which resilience to stressors decreased. The risk of frailty increases with age or incidence of disease. Gradually consid- ered more as the hallmark geriatric syndrome and foreshad- owing of other geriatric syndromes, including falls, fractures, delirium, and incontinence.

Differential diagnosis of frailty requires ruling out other underlying medical or physiological issues which might drive symptoms of frailty. These conditions include:

1. Depression
2. Malignancy - Lymphoma, multiple myeloma, occult solid tumors
3. Rheumatologic disease - Polymyalgia rheumatica, vas- culitis
4. Endocrinologic disease - Hyper- or hypothyroidism, di- abetes mellitus
5. Cardiovascular disease - Hypertension, heart failure, coronary artery disease, peripheral vascular disease
6. Renal disease - Renal insufficiency
7. Hematologic disease - Myelodysplasia, iron deficiency, and pernicious anemia
8. Nutritional deficits - Vitamin deficiencies
9. Neurologic disease - Parkinson disease, vascular de- mentia, serial lacunar infarcts

Most research identifies frailty based on the five Fried frailty criteria (slowness, weakness, low physical activity, ex- haustion and shrinkage) and divides participants into three stages: non-frail, pre-frail and frail. The above stages de- termined with scores in the social (social network type, in- formal care use, loneliness), psychological (psychological distress, mastery, self-management) and physical (chronic diseases, GARS IADL-disability, OECD disability) domains [b3]. Despite the prevalence of Fried criteria, there are dis- similarities in methods used to evaluate frailty between dif- ferent studies. Another approach to assess frailty is the frailty index approach, which sees frailty as accumulations of deficits beginning from cellular level, and quantification relies on counting the amounts of deficits among manifold organ systems.

Regardless of measurement methods, patients with frailty have their physical function declined and risk of adverse health outcomes augmented.

Epidemiology of frailty

The prevalence of frailty in those who have CKD have a larger span: from 7% in community-dwellers to 73% in a cohort of patients on hemodialysis [b3].

Pathophysiology

Two leading hypotheses are plausible to explain the re- lationship between frailty and inflammatory-related disease. One mechanism is “punished inefficiency,” which indicates the sequential effect of impairments in one system on stress and inefficiencies in other systems. The second mecha- nism, “shared pathophysiology,” suggests inflammation be- ing a probable etiological cause of frailty, inflammatory- related disease has a high prevalence in frail older people.

2 PATRICK YIHONG WU

Mortality

Frailty is associated with higher mortality risk, and vary- ing hazard ratios (HR) depends on frailty definitions and pop- ulations. In the longitudinal Women’s Health Initiative Ob- servational Study, mortality rose in those with baseline frailty (HR 1.71; 95% CI 1.48-1.97) [b1]. In another study, com- pared with robust men, it was twice the mortality for frail men (HR 2.05; 95% CI 1.55-2.72) [b2].

Complications

Chronic kidney disease can affect almost every part of your body. Potential complications may include fluid re- tention, high blood pressure, or pulmonary edema. Hy- perkalemia is probable, which is capable of damaging the heart’s function, being life-threatening. Cardiovascular dis- ease, weak bones, anemia, decreased sex drive, erectile dys- function or reduced fertility may be accompanying. Besides, damage to central nervous system, leading to difficulty con- centrating, personality changes or seizures is likely. Other complications like decreased immune response, pericardi- tis, pregnancy complications that carry risks for the mother and the developing fetus, and irreversible damage to kidneys (end-stage kidney disease) making patients eventually need- ing either dialysis or a kidney transplant for survival.

Test

Some claim that Sánchez-García et al. (2017), however, others don’t think that way (Mathiesen et al., 2019).

Comments

Why is this shit always blocking me from adding book-

Ach so, this motherfucker shit TexMaker needs me to press F1 and F11 like crazily, again and again. Am I play- ing piano? I couldn’t figure it out...HAHAHA (Streur et al., 2018).

Oh I found out finally after a 2-hour search. The package hyperref gives PDF bookmarks, but it also interferes with apa 6th \cite. Here comes the package natbib, in which citation with parentheses is \citep, who copes with the problem left by the package hyperref. Problem solved!

References

Mathiesen, J. S., Kroustrup, J. P., Vestergaard, P., Poulsen,

P. L., Stochholm, K., Rasmussen, Å. K., . . . others (2019). Survival and long-term biochemical cure in medullary thyroid carcinoma in denmark 1997-2014: A nationwide study. *Thyroid*(ja).

Sánchez-García, S., Gallegos-Carrillo, K., Espinel- Bermudez, M. C., Doubova, S. V., Sánchez-Arenas, R., García-Peña, C., . . . Briseño-Fabian, S. C. (2017). Comparison of quality of life among community-dwelling older adults with the frailty phenotype. *Quality of life research*, *26*(10), 2693–2703.

Streur, C. S., Schafer, C. L., Garcia, V. P., & Wittmann,

D. A. (2018). “i don’t know what i’m doing. . . i hope i’m not just an idiot”: The need to train pediatric urologists to discuss sexual and reproductive health care with young women with spina bifida. *The journal of sexual medicine*, *15*(10), 1403–1413.

Studzinska-Sroka, E., Galanty, A., & Bylka, W. (2017). Atranorin-an interesting lichen secondary metabolite.

marks (

|  |  |  |
| --- | --- | --- |
| Studzinska-Sroka et al. |  | 2017 |

, )?

*Mini reviews in medicinal chemistry*, *17*(17), 1633–1645.